Categories
News Technology News Uncategorized

Neuralink’s Clinical Study in the UK: What You Need to Know

Neuralink initiates UK clinical study on brain implants for paralysis, aiming to evaluate safety and effectiveness.

Neuralink Launches Clinical Study in Great Britain

Elon Musk’s brain implant company Neuralink is launching a clinical study in Great Britain. The goal is to test its brain chips in patients with severe paralysis. The study will be conducted in partnership with University College London Hospitals trust and Newcastle Hospitals.

Key Highlights

  • Study Objective: The study aims to evaluate the safety of Neuralink’s brain-computer interface (BCI) technology. It also examines its effectiveness in enabling people with severe paralysis to control devices with their thoughts.
  • Eligible Patients: Patients living with paralysis due to spinal cord injuries qualify to participate in the study. Patients with Amyotrophic Lateral Sclerosis (ALS) are also eligible.
  • Current Users: Five patients with severe paralysis are currently using Neuralink’s device. They control digital tools and physical tools with their thoughts.

Funding and Valuation

  • Recent Funding: Neuralink raised $650 million in its latest funding round last month, bringing its total funding to approximately $1.3 billion.
  • Valuation: The company is valued at roughly $9 billion, according to PitchBook.

Background

  • Human Trials: Neuralink began human trials in 2024. This happened after resolving safety concerns flagged by the US Food and Drug Administration. The administration had initially rejected the company’s application in 2022.
  • Potential Applications: Neuralink’s BCI technology has potential applications in treating various neurological disorders, including paralysis, blindness, and mental health conditions

Leave a Reply